Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by using a patient’s own T-cells to target tumors. However, they can cause rare but potentially fatal cardiac inflammation ...
The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...
Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for ...
Mount Sinai analysis looks at the effectiveness of electrocardiograms analyzed via deep learning as a tool for early COPD detection ...
Successful management of denture-associated candidiasis relies heavily on mechanical disinfection rather than pharmacologic ...
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally. Effective management ...
The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...
The treatment of chronic obstructive pulmonary disease (COPD) has been guided for decades by robust clinical practice guidelines (CPGs), such as NICE1 and GesEPOC,2 as well as international ...
A recent study published in the journal of Radiology showed that dynamic chest radiography (DCR) may serve as an effective ...
Regarding who can use these inhalers, NHS guidelines state: "Most adults can use beclometasone inhalers for asthma or COPD.
Objectives In patients with chronic obstructive pulmonary disease (COPD), severe exacerbations (ECOPDs) impose significant morbidity and mortality. Current guidelines emphasise using ECOPD history to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback